Biopharma firm I-Mab tees up $100m ADS listing
Chinese biopharmaceutical firm I-Mab has set the ball rolling for a potential $100m Nasdaq IPO, having filed a prospectus with the US regulator on Tuesday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: